Protara Therapeutics Competitors

Protara Therapeutics (NASDAQ:TARA) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Protara Therapeutics and Agenus, as reported by MarketBeat.com.

Protara Therapeutics currently has a consensus target price of $47.6667, indicating a potential upside of 246.67%. Agenus has a consensus target price of $8.00, indicating a potential upside of 153.16%. Given Protara Therapeutics' higher possible upside, research analysts clearly believe Protara Therapeutics is more favorable than Agenus.

Institutional & Insider Ownership

83.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 53.4% of Agenus shares are held by institutional investors. 45.7% of Protara Therapeutics shares are held by insiders. Comparatively, 4.7% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Protara Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares Protara Therapeutics and Agenus' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Protara Therapeutics and Agenus' gross revenue, earnings per share and valuation.

Protara Therapeutics has higher earnings, but lower revenue than Agenus.

Summary

Protara Therapeutics beats Agenus on 6 of the 9 factors compared between the two stocks.

Protara Therapeutics (NASDAQ:TARA) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, risk, valuation and profitability.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Protara Therapeutics and Precision BioSciences, as provided by MarketBeat.

Protara Therapeutics currently has a consensus price target of $47.6667, suggesting a potential upside of 246.67%. Precision BioSciences has a consensus price target of $20.00, suggesting a potential upside of 81.49%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Precision BioSciences.

Earnings and Valuation

This table compares Protara Therapeutics and Precision BioSciences' top-line revenue, earnings per share and valuation.

Protara Therapeutics has higher earnings, but lower revenue than Precision BioSciences.

Insider & Institutional Ownership

83.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of Precision BioSciences shares are owned by institutional investors. 45.7% of Protara Therapeutics shares are owned by company insiders. Comparatively, 14.3% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Protara Therapeutics and Precision BioSciences' net margins, return on equity and return on assets.

Risk & Volatility

Protara Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 2.08, meaning that its share price is 108% more volatile than the S&P 500.

Summary

Protara Therapeutics beats Precision BioSciences on 8 of the 11 factors compared between the two stocks.

Poseida Therapeutics (NASDAQ:PSTX) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Insider & Institutional Ownership

41.1% of Poseida Therapeutics shares are owned by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are owned by institutional investors. 19.0% of Poseida Therapeutics shares are owned by company insiders. Comparatively, 45.7% of Protara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Poseida Therapeutics and Protara Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Poseida Therapeutics and Protara Therapeutics' revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Poseida Therapeutics and Protara Therapeutics, as reported by MarketBeat.

Poseida Therapeutics currently has a consensus price target of $25.00, suggesting a potential upside of 169.40%. Protara Therapeutics has a consensus price target of $47.6667, suggesting a potential upside of 246.67%. Given Protara Therapeutics' higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than Poseida Therapeutics.

Summary

Protara Therapeutics beats Poseida Therapeutics on 3 of the 5 factors compared between the two stocks.

Compugen (NASDAQ:CGEN) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

63.4% of Compugen shares are held by institutional investors. Comparatively, 83.1% of Protara Therapeutics shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 45.7% of Protara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Compugen has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.

Valuation & Earnings

This table compares Compugen and Protara Therapeutics' gross revenue, earnings per share and valuation.

Protara Therapeutics has lower revenue, but higher earnings than Compugen.

Profitability

This table compares Compugen and Protara Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Compugen and Protara Therapeutics, as reported by MarketBeat.com.

Compugen currently has a consensus target price of $20.7143, suggesting a potential upside of 153.85%. Protara Therapeutics has a consensus target price of $47.6667, suggesting a potential upside of 246.67%. Given Protara Therapeutics' higher possible upside, analysts clearly believe Protara Therapeutics is more favorable than Compugen.

Summary

Compugen beats Protara Therapeutics on 5 of the 9 factors compared between the two stocks.

Protara Therapeutics (NASDAQ:TARA) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Protara Therapeutics and DBV Technologies, as reported by MarketBeat.com.

Protara Therapeutics currently has a consensus target price of $47.6667, suggesting a potential upside of 246.67%. DBV Technologies has a consensus target price of $7.0714, suggesting a potential upside of 40.87%. Given Protara Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protara Therapeutics is more favorable than DBV Technologies.

Earnings & Valuation

This table compares Protara Therapeutics and DBV Technologies' gross revenue, earnings per share (EPS) and valuation.

Protara Therapeutics has higher earnings, but lower revenue than DBV Technologies.

Profitability

This table compares Protara Therapeutics and DBV Technologies' net margins, return on equity and return on assets.

Risk and Volatility

Protara Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 2.91, indicating that its stock price is 191% more volatile than the S&P 500.

Institutional & Insider Ownership

83.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of DBV Technologies shares are owned by institutional investors. 45.7% of Protara Therapeutics shares are owned by company insiders. Comparatively, 15.3% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Protara Therapeutics beats DBV Technologies on 5 of the 9 factors compared between the two stocks.

Protara Therapeutics (NASDAQ:TARA) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Profitability

This table compares Protara Therapeutics and Curis' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations for Protara Therapeutics and Curis, as reported by MarketBeat.

Protara Therapeutics presently has a consensus target price of $47.6667, indicating a potential upside of 246.67%. Curis has a consensus target price of $12.00, indicating a potential upside of 31.43%. Given Protara Therapeutics' higher probable upside, equities research analysts plainly believe Protara Therapeutics is more favorable than Curis.

Institutional and Insider Ownership

83.1% of Protara Therapeutics shares are held by institutional investors. Comparatively, 34.7% of Curis shares are held by institutional investors. 45.7% of Protara Therapeutics shares are held by company insiders. Comparatively, 7.3% of Curis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Protara Therapeutics has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500. Comparatively, Curis has a beta of 3.29, indicating that its share price is 229% more volatile than the S&P 500.

Earnings & Valuation

This table compares Protara Therapeutics and Curis' top-line revenue, earnings per share and valuation.

Protara Therapeutics has higher earnings, but lower revenue than Curis.

Summary

Protara Therapeutics beats Curis on 6 of the 9 factors compared between the two stocks.